Plasma and IgGs from patients with lupus anticoagulant induce tissue factor in monocytes: a possible risk factor for thrombosis

Le, Dzung; Ho, Diep; Olsen, Jan Ole; Østerud, Bjarne

doi:10.1111/j.1538-7836.2010.03933.x

Cited by 7 publications

(2 citation statements)

References 12 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The above results have not resolved the persisting controversy of the presence, synthesis and functional activity of TF in platelets. In contrast to the reports above, we have failed to detect TF antigen or activity in resting platelets or platelets of whole blood stimulated with LPS, LPS in combination with PMA (48) or lupus anticoagulant antibodies (IgG), the latter being more effective in inducing TF expression in monocytes than is LPS (44). Similarly, TRAP activation of whole blood or isolated platelets in the absence or presence of LPS, failed to induce any TF antigen that could be detected in an ELISA assay or by its activity.…”

Section: Tf In Platelets?contrasting

confidence: 99%

Tissue factor in blood cells and endothelial cells

Østerud¹

2012

Front Biosci

View full text Add to dashboard Cite

There are contradictory reports about the synthesis and expression of TF antigen/activity in blood cells and plasma and in the surrounding environment of endothelial cells. In this review article we focus on the many divergent findings on the expression and presence of TF in various blood cells, plasma and endothelial cells in normal and pathological states. The widespread use of antibodies with inferior and misleading specificity and TF activity assays with low sensitivity/specificity, may be the major explanation for all the controversy. Based on our own experience and many other recent reports, pertaining to the concept of so called blood borne TF, we conclude that TF is exclusively expressed in and associated with circulating monocytes in blood of healthy individuals. However, several pathological conditions are associated with activated monocytes, shedding TF-rich microparticles that are transferred to activated platelets, neutrophils, and endothelial cells.

show abstract

Section: Tf In Platelets?contrasting

confidence: 99%

Tissue factor in blood cells and endothelial cells

Østerud¹

2012

Front Biosci

View full text Add to dashboard Cite

show abstract

“…However, one cannot exclude a scenario of monocyte origin for this TF, involving monocyte derived TF-positive microparticles binding to activated neutrophils in the circulation. We failed to see any induction of TF in neutrophils when isolated cells were incubated with IgG from patients with lupus anticoagulant, in contrast to the very high level of TF induced by the same IgG in monocytes of whole blood (44).…”

Section: Tf In Neutrophilscontrasting

confidence: 85%

Tissue factor in blood cells and endothelial cells

Østerud

Bjørklid²

2012

Front Biosci

View full text Add to dashboard Cite

Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism

Kim

Song

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

We investigated the clinical significance of the absolute monocyte count (AMC) as a predictor of the response to anticoagulation and survival in lung cancer patients with venous thromboembolism (VTE). We retrospectively reviewed 1707 patients with pathologically proven lung cancer who visited the hospital between July 2008 and May 2014. Among them, the clinical data of patients newly diagnosed with VTE and treated with anticoagulation were compared between the low and high AMC groups according to the median value of AMC (640/μL) at the time of VTE diagnosis. The incidence of VTE was 7.9 % during the study period. Most of the patients had non-small-cell lung cancer (82.1 %), stage IV (64.2 %), and pulmonary thromboembolism (76.1 %) and were incidentally diagnosed with VTE (76.9 %). The patients' characteristics and laboratory values were not significantly different between the low and high AMC groups. Among patients available for evaluation of the response to anticoagulation, the high AMC group was significantly more refractory to anticoagulation than the low AMC group (no response to anticoagulation, 21.7 vs. 6.8 %, respectively; p = 0.044). Additionally, the high AMC group showed worse overall survival (OS) than the low AMC group (median, 9.6 vs. 5.9 months; p = 0.038). On multivariate analysis, high AMC, low albumin, and advanced stage were independent poor prognostic factors for OS. High AMC is associated with refractoriness to anticoagulation and poor prognosis in lung cancer patients with VTE.

show abstract

Plasma and IgGs from patients with lupus anticoagulant induce tissue factor in monocytes: a possible risk factor for thrombosis

Cited by 7 publications

References 12 publications

Tissue factor in blood cells and endothelial cells

Tissue factor in blood cells and endothelial cells

Tissue factor in blood cells and endothelial cells

Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism

Contact Info

Product

Resources

About